

Seeking in utero Treatments for Rare Diseases

The Impulse by Chiesi, the Open Innovation team within the global research-oriented biopharmaceutical group, is launching a call for **innovative *in utero* therapeutic solutions for the treatment of rare diseases**. Their focus is on approaches that enable early intervention to **prevent or significantly reduce disease burden before birth**.



Approaches of Interest:

- Indications of highest interest include inborn errors of metabolism; dermatologic, haematologic, and immunologic conditions; endocrine-metabolic diseases; and adjacent areas such as kidney disease
- Ultra-rare diseases (≤ 1 in 50,000) will be considered
- Treatments capable of crossing the placenta are also of interest
- Any therapeutic modalities that lead to rare disease treatment *in utero* would be accepted if they meet the criteria below:
 - Demonstrate or plausibly support biological efficacy
 - Be suitable for prenatal administration
 - Present a clear translational pathway, including delivery, safety, and durability considerations

Out of Scope:

- Opportunities related to oncology and infectious disease

Developmental Stages of Interest:

- Opportunities from basic research phase to registration are within scope
- Opportunities should provide, at a minimum, *in vitro* data, a detailed outline of the proposed next research steps, and the funding required to achieve the upcoming research milestones

Submission Information and Opportunity for Collaboration

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Applicants are strongly encouraged to include a slide-deck (or similar presentation) outlining their solution. The Impulse by Chiesi welcomes submissions from all applicants, including early-stage researchers, using this **submission form** to describe their research and proposed next steps. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

The Impulse by Chiesi is open to a range of collaboration models, including support for small proof-of-concept or pilot studies to validate solutions that align with its needs. Details regarding intellectual property and licensing will be discussed on a case-by-case basis. By submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Company profiles
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **10th June 2026 - 10:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io

